Navigation Links
Toward understanding the dangers of the fake marijuana called 'Spice' or 'K2'
Date:10/2/2013

The harmful effects of increasingly popular designer cannabis products called "Spice" or "K2" have puzzled scientists for years, but now a group of researchers is reporting progress toward understanding what makes them so toxic. The study, published in the ACS journal Analytical Chemistry, describes development of a method that could someday help physicians diagnose and treat the thousands of young adults and teens who end up in emergency rooms after taking the drugs.

Jeffery Moran and colleagues note that synthetic marijuana, often marketed as "natural incense," "potpourri," Spice or K2, is a significant public health concern, and 1 in 9 high school seniors admit recent use. The products appear across the United States and Europe, and are the second most popular drug after real marijuana for many American teens and young adults. The substances produce a "high," but also can cause a wide range of dangerous side effects including seizures, hallucinations, severe kidney damage, psychotic behavior and heart attacks. Scientists are quickly playing catch-up to understand how these fake pot products work in order to identify them in users' urine and to treat the devastating health effects, which, in some cases, plague users for months after they initially take it.

To gain insight into the effects of designer marijuana products, Moran's team developed a new method and used it to study how the body processes two popular forms in Spice and K2, known as JWH-018 and AM2201. Urine samples from 15 people who tested positive for use showed significant differences in how the individuals' bodies processed the drugs. This finding could help explain why some people experience more severe effects from the drugs than others.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1

Related biology news :

1. Insect-inspired super rubber moves toward practical uses in medicine
2. Toward a safer form of acetaminophen
3. New materials, progress toward an HIV vaccine, and more at meeting of crystallographers
4. UCLA stem cell gene therapy for sickle cell disease advances toward clinical trials
5. Toward broad-spectrum antiviral drugs for common cold and other infections
6. NREL drives toward the future with fuel cell EVs
7. Engineered stem cell advance points toward treatment for ALS
8. A giant step toward miniaturization
9. The large-scale EU project EU BON: Towards integration with its global counterpart GEO BON
10. Towards more sustainable construction
11. Report: Water and Agriculture in Canada: Towards Sustainable Management of Water Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2016)... DUBLIN , Nov 15, 2016 Research ... - Global Forecast to 2021" report to their offering. ... ... reach USD 16.18 Billion by 2021 from USD 6.21 Billion in ... Growth of the bioinformatics market is driven by ...
(Date:6/27/2016)... Research and Markets has announced the addition of the ... The report forecasts the biometrics ... a CAGR of 12.28% during the period 2016-2020. ... with inputs from industry experts. The report covers the market landscape ... includes a discussion of the key vendors operating in this market. ...
(Date:6/22/2016)... , June 22, 2016 On Monday, the ... to industry to share solutions for the Biometric Exit ... Customs and Border Protection (CBP), explains that CBP intends ... departing the United States , in ... to defeat imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/8/2016)...   Biocept, Inc . (NASDAQ: ... actionable liquid biopsy tests to improve the management ... its Target Selector™ Circulating Tumor Cell platform demonstrated ... of actionable biomarkers in patients with metastatic breast ... Cannon Research Institute (SCRI), the research arm of ...
(Date:12/7/2016)... ... 07, 2016 , ... A new study published in the ... treated, advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute for ... blood sampling may improve the value of a blood-based test.” The study was ...
Breaking Biology Technology: